je.st
news
Tag: presented
The 2015 ICIS Kavaler Award to be Presented to Dow Chairman & CEO Andrew Liveris
2015-06-23 07:00:00| Coatings World Breaking News
Tags: presented
award
andrew
ceo
MBK Discusses Wearable Technology Designs: Presented by Jason Zajac at University of San Francisco/UC Berkeley
2015-06-22 12:31:11| Industrial Newsroom - All News for Today
BK Tape Solutions Chatsworth, CA Jason Zajac, Vice President of Sales for MBK Tape Solutions, presented to the University of San Francisco/ UC Berkeley, Master of Translational Medicine (MTM) team about the latest stick to skin adhesives they engineer as well as the multi-layer lamination methods MBK has pioneered...
Tags: technology
university
san
presented
PharmaCyte Biotech's Diabetes Treatment to Be Presented at Austrodrugs 2015
2015-06-12 21:11:19| Biotech - Topix.net
PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-BoxA , today reported that the company's diabetes treatment and the research program of its international Diabetes Consortium will be presented at the Austrodrugs 2015 conference to be held on June 12 in Vienna, Austria. The Austrodrugs conference is one of the leading disease treatment development meetings in central Europe.
Tags: presented
treatment
diabetes
biotechs
1st major utility proposal for EV charging infrastructure presented to CPUC
2015-06-05 11:55:33| Green Car Congress
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »